

Biography
His education includes a decade of postgraduate training in complex general surgical oncology, as well as a PhD in immunology with an emphasis on cancer biology. He completed a clinical fellowship at Johns Hopkins University and continued his research at the postdoctoral level in the laboratory of Dr. Elizabeth Jaffee. His research focus is on advancing the field of cancer immunology and harnessing his findings to improve immunotherapies.
He was the principal investigator of two studies examining the immune response to pancreatic cancer, including one funded by the National Cancer Institute.
Dr. Delitto has presented the findings of his research at conferences such as the American Association for Cancer Research, Society for the Immunotherapy of Cancer, American Association of Immunologists, American College of Surgeons, Academic Surgical Congress and Pancreas Club. In addition to cancer immunology, he has also presented work focused on cancer cachexia, surgical outcomes, translational experimental models and a variety of other oncologic topics.
He has published original work in Nature Communications, the Journal of the National Cancer Institute, Cancer Research, Clinical Cancer Research, and other high impact journals. He is also a reviewer for Annals of Surgery, Scientific Reports, Surgery, Tumor Biology, Journal of Surgical Research, PLOS ONE, and the Journal of Translational Medicine.
Dr. Delitto has earned numerous honors related to clinical excellence, teaching and research. He is board certified by the American Board of Surgery and a member of the Society of Surgical Oncology, American Association for Cancer Research and American Association of Immunologists.
Professional Summary
Professional Education
- Board Certification: American Board of Surgery, Complex General Surgical Oncology (2022)
- Residency: University of Florida Dept of General Surgery (2019) FL
- Board Certification, American Board of Surgery, Complex General Surgical Oncology (2022)
- Fellowship: Johns Hopkins University Surgery Program (2021) MD
- Board Certification: American Board of Surgery, General Surgery (2019)
- PhD Training: University of Florida Office of the Registrar (2016) FL
- Medical Education: University of Pittsburgh School of Medicine Registrar (2011) PA
Publications
-
Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection.
Delitto, D., Zabransky, D. J., Chen, F., Thompson, E. D., Zimmerman, J. W., Armstrong, T. D., … Jaffee, E. M. (2021). Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. Oncoimmunology, 10(1), 2001159. -
GSK3 suppression upregulates ß-catenin and c-Myc to abrogate KRas-dependent tumors.
Kazi, A., Xiang, S., Yang, H., Delitto, D., Trevino, J., Jiang, R. H., … Sebti, S. M. (2018). GSK3 suppression upregulates ß-catenin and c-Myc to abrogate KRas-dependent tumors. Nature Communications, 9(1), 5154. -
Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy.
Delitto, D., George, T. J., Loftus, T. J., Qiu, P., Chang, G. J., Allegra, C. J., … Iqbal, A. (2018). Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy. Journal of the National Cancer Institute, 110(5), 460–466. -
Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment.
Delitto, D., Delitto, A. E., DiVita, B. B., Pham, K., Han, S., Hartlage, E. R., … Wallet, S. M. (2017). Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. Cancer Research, 77(3), 672–683. -
Targeting tumor tolerance: A new hope for pancreatic cancer therapy?
Delitto, D., Wallet, S. M., & Hughes, S. J. (2016). Targeting tumor tolerance: A new hope for pancreatic cancer therapy? Pharmacology & Therapeutics, 166, 9–29. -
Radiographic, Biochemical, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best?
Javadi, C., Chang, J., Forgo, E., Ahmad, M. U., Fisher, G. A., Chang, D. T., … Poultsides, G. A. (2022). Radiographic, Biochemical, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best? ANNALS OF SURGICAL ONCOLOGY. SPRINGER. -
Surgical solution for a paraneoplastic neurodegenerative disorder
Muhammad, H., Strayve, D. G., Narayan, R. R., Blayney, D. W., & Delitto, D. (2022). Surgical solution for a paraneoplastic neurodegenerative disorder. TRAUMA SURGERY & ACUTE CARE OPEN, 7(1). -
Surgical solution for a paraneoplastic neurodegenerative disorder.
Muhammad, H., Strayve, D. G., Narayan, R. R., Blayney, D. W., & Delitto, D. (2022). Surgical solution for a paraneoplastic neurodegenerative disorder. Trauma Surgery & Acute Care Open, 7(1), e000928. -
First Recurrence of Synovial Sarcoma Presenting With Solitary Pancreatic Mass
Narayan, R. R., Charville, G. W., Delitto, D., & Ganjoo, K. N. (2022). First Recurrence of Synovial Sarcoma Presenting With Solitary Pancreatic Mass. CUREUS JOURNAL OF MEDICAL SCIENCE, 14(6). -
Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy.
Ivey, G. D., Shoucair, S., Delitto, D. J., Habib, J. R., Kinny-Koster, B., Shubert, C. R., … He, J. (2022). Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. World Journal of Surgery. -
First Recurrence of Synovial Sarcoma Presenting With Solitary Pancreatic Mass.
Narayan, R. R., Charville, G. W., Delitto, D., & Ganjoo, K. N. (2022). First Recurrence of Synovial Sarcoma Presenting With Solitary Pancreatic Mass. Cureus, 14(6), e26356. -
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin.
Foster, D. S., Januszyk, M., Delitto, D., Yost, K. E., Griffin, M., Guo, J., … Longaker, M. T. (2022). Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin. Cancer Cell. -
Age-related changes in pancreatic fibroblasts promote growth and progression of pancreatic cancer
Zabransky, D. J., Chhabra, Y., Fane, M. E., Delitto, D., Zimmermann, J. W., Jaffee, E. M., & Weeraratna, A. T. (2022). Age-related changes in pancreatic fibroblasts promote growth and progression of pancreatic cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
Practice Locations
Gastrointestinal (GI) Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CAGastrointestinal (GI) Cancer Program in Palo Alto
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Sarcoma Program at Blake Wilbur Building Palo Alto, CA
Palo Alto, CASarcoma Program at Blake Wilbur Building
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(31 reviews)
View More »
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

- Send referrals online
- View referral status
- Access medical records